NDA 050138 · King Pharms LLC
Bicillin C-R
Penicillin G Benzathine, Penicillin G Procaine · Injection
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1953
May 18, 1953
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
802
170 Phase 3, 84 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Penicillin G Benzathine" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Evaluation of an Intensive 3-round MDA Strategy Towards Yaws EradicationPivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT03490123 · 56,000 participants · Start Apr 16, 2018 · Primary completion Apr 1, 2020
Drug: R1-Total community treatment with azithromycin; R2-Total community treatment with azithromycin and 3 more · For: Yaws
Sites: Kavieng, Papua New Guinea
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New GuineaPivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT01955252 · 16,000 participants · Start Mar 2013 · Primary completion May 2017
Drug: Azithromycin · For: Yaws
Sites: Londolovit, Papua New Guinea
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisPivotal-lookingRecruiting
Scandinavian Critical Care Trials GroupAcademic, hospital or other
NCT06184659 · 5,800 participants (planned) · Start Jun 26, 2025 · Primary completion Jun 30, 2028
Drug: Meropenem; Piperacillin/Tazobactam · For: Sepsis; Septic Shock
Sites: Copenhagen, Denmark · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Bicillin C-R (Pen G Benz/Pen G Procaine) · HCPCS J0558
2024 spending
$13K
Beneficiaries
66
92 claims
Per beneficiary
$191
2024 ASP limit $18.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $65,854 |
| 2021 | $49,969 |
| 2022 | $53,529 |
| 2023 | $64,314 |
| 2024 | $12,615 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azithromycin vs penicillin G benzathine for early syphilis: A meta-analysis of randomized controlled trials.
Li Y, Jiang G · Dermatol Ther 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis.
Hook EW, Stephens J, Ennis DM · Ann Intern Med 1999 · Clinical Trial, Comparative Study
- Azithromycin vs. benzathine penicillin G for early syphilis: a meta-analysis of randomized clinical trials.
Bai ZG, Yang KH, Liu YL, et al. · Int J STD AIDS 2008 · Meta-Analysis, Systematic Review
- Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
Beaton A, Okello E, Rwebembera J, et al. · N Engl J Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis.
Riedner G, Rusizoka M, Todd J, et al. · N Engl J Med 2005 · Clinical Trial, Comparative Study
- Serum levels of penicillin in basic trainees in the U.S. Army who received intramuscular penicillin G benzathine.
Bass JW, Longfield JN, Jones RG, et al. · Clin Infect Dis 1996 · Clinical Trial
Sponsor: King Pharms LLC · Also marketed as Bicillin C-R 900/300
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.